89bio, Inc.: management transactions · United States · SEC (Form 4)

About 89bio, Inc.

89bio, Inc. (ticker: ETNB) is a clinical-stage biopharmaceutical company listed on the NASDAQ market in the United States. The company is focused on developing and commercializing innovative therapies for liver and cardiometabolic diseases, with corporate headquarters in San Francisco, California, and operations in Herzliya, Israel. 89bio traces its roots to 89Bio Ltd., which was incorporated in Israel in January 2018; the U.S. parent, 89bio, Inc., was incorporated in June 2019 as part of an internal reorganization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1785173/000095017025029243/etnb-20241231.htm)) The company’s investment case has been centered on its lead product candidate, pegozafermin, a specifically engineered glycoPEGylated FGF21 analog. Pegozafermin is being developed for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) with advanced fibrosis, including compensated cirrhosis, as well as for severe hypertriglyceridemia (SHTG). From a scientific and commercial standpoint, 89bio is targeting high-unmet-need areas where treatment options have historically been limited and where the addressable market could be meaningful if clinical and regulatory execution is successful. ([ir.89bio.com](https://ir.89bio.com/news-releases/news-release-details/89bio-inc-announces-agreement-be-acquired-roche/)) Competitive positioning in this space is challenging. 89bio operates in a crowded and highly competitive liver/metabolic disease landscape that includes large pharmaceutical companies and well-financed biotech peers pursuing adjacent or overlapping indications. Rather than building a broad commercial portfolio, 89bio has pursued a focused, single-asset strategy designed to maximize the value of pegozafermin. That strategy offers substantial upside if data are positive, but it also creates pronounced binary risk tied to late-stage clinical outcomes, regulatory decisions, and partnering or commercialization outcomes. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1785173/000095017025029243/etnb-20241231.htm)) The most important recent corporate development was the September 18, 2025 announcement that Roche agreed to acquire 89bio. Under the announced terms, 89bio stockholders were to receive $14.50 per share in cash at closing, plus a non-tradeable CVR worth up to an additional $6.00 per share in cash, implying total potential equity value of about $3.5 billion. 89bio stated that it would continue to operate as a separate and independent company until the transaction closes. ([ir.89bio.com](https://ir.89bio.com/news-releases/news-release-details/89bio-inc-announces-agreement-be-acquired-roche/)) For French-speaking investors in France, Belgium, and Switzerland, ETNB is therefore best understood as a clinical biotech with a concentrated pipeline, significant upside tied to one lead asset, and a near-term strategic overlay from the Roche acquisition process. The key variables are no longer only the long-term clinical potential of pegozafermin, but also the completion of the transaction and any remaining milestones that may affect value realization. ([ir.89bio.com](https://ir.89bio.com/news-releases/news-release-details/89bio-inc-announces-agreement-be-acquired-roche/))